Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 219Recurrence 23Neoplasms, Plasma Cell 15Immunoglobulin Light-chain Amyloidosis 14Neoplasms 12Lymphoma, Non-Hodgkin 6Smoldering Multiple Myeloma 5Leukemia, Myeloid, Acute 4Plasmacytoma 3Paraproteinemias 3Leukemia, Plasma Cell 3Hematologic Neoplasms 3Hematologic Diseases 3Amyloidosis 3Neoplasm, Residual 2Hodgkin Disease 2Disease 2Corneal Diseases 2Blood Protein Disorders 2Acute Kidney Injury 2Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × daratumumab × Plasma cell × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡